Open AccessAducanumab: a new phase in therapeutic development for Alzheimer’s disease?
Author(s) -
Lalli Giovanna,
Schott Jonathan M,
Hardy John,
De Strooper Bart
Publication year - 2021
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.202114781
Subject(s) - disease , drug development , drug , medicine , alzheimer's disease , mechanism (biology) , drug discovery , amyloid (mycology) , pharmacology , bioinformatics , pathology , biology , philosophy , epistemology
On 7 June , the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain.